ARID3A and colorectal cancer: To validate if WNT directly regulates Arid3a without change of cell fate, we switched to the human colorectal cancer cell line LS174T—with activated WNT signaling driven by β-catenin mutation—by treating them with two different doses of LF3 inhibitor (10 and 30 μΜ) for 24 h qRT-PCR analysis showed a robust upregulated expression of ARID3A and downregulation of WNT target AXIN2 in both doses (Fig. 2 D).